Arecor Limited announces that its abstract titled ‘Phase I study investigating the PD, PK and safety of AT247 in comparison to insulin aspart, NovoRapid®, and fast insulin aspart, Fiasp®, has been selected for oral presentation at the upcoming European Association for the Study of Diabetes virtual meeting which will be held from 21-25 September 2020.
September 21, 2020
· 1 min read